CVBT Announces Positive Pre-Clinical Animal Study Results in Peripheral Vascular Diseases, or ''PVD''.HENDERSON, Nev. -- PVD PVD abbr. peripheral vascular disease PVD Peripheral vascular disease, see there Affects 8 to 12 million Americans CardioVascular BioTherapeutics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CVBT CVBT Cardiovascular Biotherapeutics, Inc CVBT Central Virginia Battlefields Trust (Fredericksburg, VA Civil War history organization) ) announced today that its pre-clinical animal study has shown positive results for its drug candidate Cardio Vascu-Grow(TM) in treating Peripheral Vascular Disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. , or "PVD." PVD is a disease in which the arteries of the leg become blocked, leading, in many cases, to intense pain and suffering for these patients. The Company's drug candidate Cardio Vascu-Grow(TM) has proven to be a potent stimulator for growing new blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. in affected areas of the legs of rabbits, thereby providing blood perfusion Blood perfusion A physiological term that refers to the process of nutritive delivery of arterial blood to a capillary bed in the biological tissue. Mentioned in: Interstitial Microwave Thermal Therapy to the leg. In its most severe form, PVD can lead to extensive tissue loss and gangrene gangrene, local death of body tissue. Dry gangrene, the most common form, follows a disturbance of the blood supply to the tissues, e.g., in diabetes, arteriosclerosis, thrombosis, or destruction of tissue by injury. , which, for many patients, results in amputation amputation (ăm'pyətā`shən), removal of all or part of a limb or other body part. Although amputation has been practiced for centuries, the development of sophisticated techniques for treatment and prevention of infection has greatly of the limb. Though there are many therapies being developed to treat PVD, there are an increasing number of limb amputations in such patients, many of whom suffer from diabetes. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the American Heart Association's 2005 report, there are 8 to 12 million Americans suffering from this malady malady /mal·a·dy/ (-ah-de) disease. mal·a·dy n. A disease, disorder, or ailment. malady a disease or illness. . Dr. Thomas Stegmann M.D., a professor, cardiovascular surgeon and Chief Clinical Officer for CVBT stated, "I have seen many of these patients on the operating table, where there was nothing we could do surgically to restore blood flow in their legs, leaving amputation as the only option. The preclinical results are promising and we will continue to investigate the use of Cardio Vascu-Grow(TM) for the treatment of Peripheral Vascular Disease." Dr. Stegmann added, "I believe if Cardio Vascu-Grow(TM) is shown to be safe and effective for the treatment of this disease, it would dramatically lower the cost of the patient's medical care, as compared to the cost of providing medical care to a diabetic patient whose leg has been amputated." Mr. Daniel C. Montano, President of CVBT, said, "Many medical doctors have been pushing us to advance this revolutionary treatment of PVD, particularly for helping their diabetic patients. We are continuing to investigate the use of our protein drug candidate in this muscle tissue group as rapidly as we can." "We recently announced that Cardio Vascu-Grow(TM) yielded positive results in pre-clinical animal studies for minimizing the Stroke-Affected Area in the Brain, and that Cardio Vascu-Grow(TM) has likewise shown positive results in accelerating the closing of Diabetic Wounds in pre-clinical animal studies," Mr. Montano further remarked. "It is exciting to report that Cardio Vascu-Grow(TM) has shown promising results in treating Peripheral Vascular Disease in animal studies compared to control groups. CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive affect of our drug candidate aimed at improving the quality of life for those suffering from Heart Disease, Stroke, Diabetic Wounds, Peripheral Vascular Disease and pledges to continue exploration for additional applications of Cardio Vascu-Grow(TM)." Persons wishing further information on the pre-clinical PVD studies should request a copy at the website www.CVBT.com. CardioVascular BioTherapeutics, Inc. (stock symbol: CVBT) is a biopharmaceutical company focused on developing a new drug for the treatment of cardiovascular diseases where the growth of new blood vessels can improve the outcome for patients with these diseases. Its drug candidate, Cardio Vascu-Grow(TM), is designed to facilitate the growth of new blood vessels in the heart and other tissues with an impaired vascular system. This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding our future revenues, cash usage and our cash flow breakeven point are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Cardio Vascu-Grow(TM), market acceptance of CardioVascular BioTherapeutics, Inc. products by our customers, future revenues, future expenses, future margins, cash usage, and financial performance. For a more detailed discussion of these and associated risks, see the Company's most recent documents filed with the Securities and Exchange Commission. Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics, Inc. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion